Stonepine Capital Management, LLC
revealed that they own 10% of CombiMatrix Corporation (NASDAQ:CBMX) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Wednesday, August 9th. The investor owns 290,010 shares of the stock worth about $2,146,074. The reporting parties listed on the disclosure included Stonepine Capital Management, LLC, Stonepine Capital, LP, Jon M Plexico and Timothy P Lynch. The filing is available through the SEC website at this link.
Stonepine Capital Management, LLC
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Separately, Essex Investment Management Co. LLC increased its position in shares of CombiMatrix Corporation by 94.4% in the second quarter. Essex Investment Management Co. LLC now owns 25,878 shares of the medical research company’s stock valued at $138,000 after buying an additional 12,564 shares during the period. Institutional investors own 11.47% of the company’s stock.
CombiMatrix Corporation (CBMX) traded up 0.68% during midday trading on Friday, reaching $7.40. The company’s stock had a trading volume of 40,871 shares. CombiMatrix Corporation has a 1-year low of $2.15 and a 1-year high of $7.90. The stock’s 50-day moving average price is $6.16 and its 200 day moving average price is $5.22. The firm’s market capitalization is $21.59 million.
CombiMatrix Corporation (NASDAQ:CBMX) last issued its earnings results on Thursday, August 3rd. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.11. CombiMatrix Corporation had a negative net margin of 15.53% and a negative return on equity of 36.07%. The company had revenue of $4.24 million during the quarter, compared to analyst estimates of $3.89 million. Equities analysts anticipate that CombiMatrix Corporation will post ($0.52) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “CombiMatrix Corporation (NASDAQ:CBMX) Stake Owned by Stonepine Capital Management, LLC” was first reported by BNB Daily and is owned by of BNB Daily. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/10-stake-of-combimatrix-corporation-nasdaqcbmx-owned-by-stonepine-capital-management-llc-updated.html.
CBMX has been the topic of several research analyst reports. Aegis initiated coverage on CombiMatrix Corporation in a research report on Thursday, July 13th. They set a “buy” rating and a $8.10 price target on the stock. Ladenburg Thalmann Financial Services cut CombiMatrix Corporation from a “buy” rating to a “neutral” rating in a research note on Friday, August 4th.
About CombiMatrix Corporation
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.
Receive News & Ratings for CombiMatrix Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix Corporation and related companies with MarketBeat.com's FREE daily email newsletter.